Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer
November 18 2019 - 4:05PM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company
committed to developing medicines that transform the lives of
people with rare neurological diseases, today announced the
appointment of Jason Tardio as Chief Commercial Officer. Mr. Tardio
brings to Ovid broad global commercial leadership experience within
the pharmaceutical and biotechnology industries, having most
recently served as Vice President and Head of the Multiple
Sclerosis franchise at Novartis.
“2020 will be a year of transformation for
Ovid,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief
Executive Officer of Ovid Therapeutics. “We expect Phase 3 data for
OV101 in Angelman syndrome and Phase 2 data from all other programs
in our clinical development portfolio. We will now begin to set in
place the commercial strategies and over time the capabilities to
ensure we are well-positioned to bring these medicines to patients.
To do this, we have strengthened our senior team with a world class
commercial leader. I am excited to welcome Jason Tardio to Ovid.
Jason is a leader who brings deep experience in within CNS, rare
disease, product launch planning and commercialization. He will lay
the foundations of our next steps as we plan this transition of our
company.”
Prior to joining Ovid, Mr. Tardio served as Vice
President and Head of the Multiple Sclerosis franchise at Novartis.
There, he was responsible for developing and managing all aspects
of the U.S. commercial plan, brand P&L, strategy development,
go-to-market modeling and day-to-day execution for Gilenya® and
Mayzent®. Prior to Novartis, Mr. Tardio held roles of
increasing responsibility at Biogen where most recently he served
as GM, Managing Director for Biogen’s Latin America South
affiliate, leading the business for Argentina, Chile and Uruguay.
Earlier at Biogen, Jason held a wide range of sales and marketing
roles of increasing responsibility, including positions in Global
Commercial Strategy, the U.S. Business Unit and at the
international affiliate level. His more than 17 years of commercial
experience in the biopharmaceutical industry began at Wyeth and
Sepracor, with roles in sales, sales training and marketing. Jason
holds a Bachelor of Science from The College of New Jersey and an
MBA in Pharmaceutical Marketing from St. Joseph’s University.
“I am very excited by the depth and progress of
the Ovid pipeline, in particular the recent advancement of OV101
(gaboxadol) into the pivotal Phase 3 NEPTUNE study for Angelman
syndrome. In addition, Ovid and Takeda’s program in rare epilepsies
is differentiated and OV935 (soticlestat) may present the
opportunity not just to reduce seizures in these patients but also
to heal the brain,” said Mr. Tardio. “This is a unique opportunity
to bring patients transformational medicines. I am honored to join
the team at Ovid and begin the planning process to establish a
thoughtful and highly successful commercial strategy.”
About Ovid TherapeuticsOvid
Therapeutics Inc. is a New York-based biopharmaceutical company
using its BoldMedicine® approach to develop medicines that
transform the lives of patients with rare neurological disorders.
Ovid has a broad pipeline of potential first-in-class medicines.
The company’s most advanced investigational medicine, OV101
(gaboxadol), is currently in clinical development for the treatment
of Angelman syndrome and Fragile X syndrome. Ovid is also
developing OV935 (soticlestat) in collaboration with Takeda
Pharmaceutical Company Limited for the potential treatment of rare
developmental and epileptic encephalopathies (DEE).
For more information on Ovid, please visit
http://www.ovidrx.com/.
Forward-Looking Statements This
press release includes certain disclosures that contain
“forward-looking statements,” including, without limitation,
statements regarding: advancing and commercializing Ovid’s product
candidates, progress, timing, scope and the potential therapeutic
benefits based on results of clinical trials for Ovid’s product
candidates; and the anticipated reporting schedule of clinical data
regarding Ovid’s product candidates. You can identify
forward-looking statements because they contain words such as
“will,” “believes” and “expects.” Forward-looking statements are
based on Ovid’s current expectations and assumptions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
may differ materially from those contemplated by the
forward-looking statements, which are neither statements of
historical fact nor guarantees or assurances of future performance.
Important factors that could cause actual results to differ
materially from those in the forward-looking statements include the
fact that initial data from clinical trials may not be indicative,
and are not guarantees, of the final results of the clinical trials
and are subject to the risk that one or more of the clinical
outcomes may materially change as patient enrollment continues
and/or more patient data become available. Additional risks that
could cause actual results to differ materially from those in the
forward-looking statements are set forth in Ovid’s filings with the
Securities and Exchange Commission under the caption “Risk
Factors”. Ovid assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Gilenya® and Mayzent® are registered trademarks
of Novartis AG.
Contacts
Investors and Media:Ovid
Therapeutics Inc.Investor Relations & Public
Relationsirpr@ovidrx.com
Or
Investors: Steve KlassBurns
McClellan, Inc.sklass@burnsmc.com (212) 213-0006
Media: Katie Engleman 1AB
katie@1abmedia.com (919) 333-7722
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2023 to Apr 2024